| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-02-07 | Pieris (Germany) | resignation | Autoimmune diseases - Cancer - Oncology | Resignation | ||
| 2017-02-07 | Minoryx Therapeutics (Spain) | member of the board of directors | nomination | Rare diseases | Nomination | |
| 2017-02-06 | Teva Pharmaceutical (Israel) | president | nomination | Nomination | ||
| 2017-02-03 | Amag Pharmaceuticals (USA - MA) Palatin Technologies (USA - NJ) | Rekynda™ (bremelanotide) | hypoactive sexual desire disorder (HSDD) in pre-menopausal women | licensing | Women health | Licensing agreement |
| 2017-02-02 | Rentschler Biotechnologie (Germany) Leukocare (Germany) | collaboration equity investment |
Technology - Services | Collaboration agreement | ||
| 2017-02-01 | Patheon (USA - NC) Roche (Switzerland) | manufacturing facility in Florence (SC) | plant acquisition | Technology - Services | Plant acquisition | |
| 2017-01-31 | Santhera Pharmaceuticals (Switzerland) | member of the board of directors | nomination | Rare diseases - Genetic diseases - Neuromuscular diseases - Ophtalmological diseases | Nomination | |
| 2017-01-31 | Onxeo (France) Institut Curie (France) | radiotherapy, DNA repair inhibitors and immunotherapy | clinical research |
Cancer - Oncology | Clinical research agreement | |
| 2017-01-31 | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) University of Cambridge (UK) | novel molecules that target and modulate the apelin receptor | research | Cardiovascular diseases | R&D agreement | |
| 2017-01-30 | Novo Nordisk (Denmark) Oxford University's Medical Sciences Division (UK) | type 2 diabetes | R&D collaboration |
Metabolic diseases | R&D agreement | |
| 2017-01-30 | Elsalys Biotech (France) | chief operating officer, chief medical officer, vice president finance | nomination | Cancer - Oncology - Ophtalmological diseases | Nomination | |
| 2017-01-30 | Exelixis (USA - CA) Takeda Pharmaceutical (Japan) | cabozantinib | advanced renal cell carcinoma and potential future indications | licensing clinical research commercialisation |
Cancer - Oncology | Licensing agreement |
| 2017-01-27 | Eli Lilly (USA - IN) Adocia (France) | BioChaperone Lispro® | type 1 and type 2 diabetes | development | Metabolic diseases | Termination of an agreement |
| 2017-01-27 | Biogen (USA - MA) Mitsubishi Tanabe Pharma (Japan) | MT-1303 | multiple sclerosis, ulcerative colitivis, inflammatory bowel disease, Crohn\'s disease | licensing | Autoimmune diseases - Inflammatory diseases - Digestive diseases | Termination of an agreement |
| 2017-01-27 | Juno Therapeutics (USA - WA) | nomination | Nomination | |||
| 2017-01-26 | Cyprotex (UK), an Evotec company (Germany) | opening of new premises | Technology - Services | Opening of new premises | ||
| 2017-01-25 | IBM (USA - NY) Lundbeck (Denmark) | psychiatric and neurological disorders | collaboration |
CNS diseases - Mental diseases - Neurological diseases | Collaboration agreement | |
| 2017-01-25 | Uniqure (The Netherlands) | senior vice-president of regulatory affairs | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-01-24 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-01-24 | Anergis (Switzerland) | chairman of the board | nomination | Allergic diseases - Inflammatory diseases - Respiratory diseases | Nomination |
